1. Lazarou J, Pomeranz B, Corey D et al. Incidence of adverse drug reactions in hospitalized patients: a metaanalysis of prospective studies. JAMA 1998;279:1200-5.
2. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA 2001;286: 2270-9.
3. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-91.
4. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
5. Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995;311:619-20.
6. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983;249:1743-5.
7. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future trends. JAMA 1999;281:824-9.
8. Venning GR. Identification of adverse reactions to new drugs. II. How were 18 important adverse reactions discovered and with what delays? BMJ 1983;286: 289-92;365-8.
9. Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000;356:1505-11.
10. Edwards R, Lindquist M, Wiholm BE et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990;336:156-8.
11. Meyboom RHB, Egherts ACG, Edwards JR et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997;16:355-65.
12. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse reaction reporting by medical practitioners in the United Kingdom. Br J Pharmacol 1995;39:223-6.
13. Kaufman DW, Shapiro S. Epidemiological assessment of drug-induced disease. Lancet 2000;356:1339-43.
14. Van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998;51:703-8.
15. Fellay J, Boubaker K, Ledergerber B et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-7.
16. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
17. Kelly JP, Auqier A, Rzany B et al. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995;48:1099-108.
18. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell's syndrome): incidence and drug etiology in France 1981-1985. Arch Dermatol 1990;126:37-42.
19. Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
20. Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiol Drug Saf 2001; 10:197-203.
21. Levine M, Walter S, Lee H, et al. Users' guides to the medical literature. IV. How to use an article about harm. JAMA 1994;271:1615-19.
22. Maistrello M, Morgutti M, Rossignoli A, Posca M. A selective guide to pharmacovigilance resources on the internet. Pharmacoepidemiol Drug Saf 1998;7:183-8.
23. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001;137:765-70.
24. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA 1999;281:841-4.
25. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1998;318:1728-33.
26. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
27. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to treat for one additional patient to be harmed". BMJ 2000;320:503-6.
Was this article helpful?